CytomX Therapeutics Inc. (CTMX) has disclosed a new risk, in the Innovation / R&D category.
CytomX Therapeutics Inc. faces significant business risks due to the early-stage development of its product candidates, such as CX-2051 and CX-801, which may fail or encounter delays impacting their commercial viability. The absence of market-ready products means the company must secure regulatory approvals and successfully commercialize its candidates to achieve profitability. Challenges such as negative clinical trial outcomes, regulatory hurdles, and manufacturing difficulties could jeopardize their development pipeline, as seen with the termination of the CX-904 program with Amgen and CX-2029 with AbbVie. Any further setbacks could materially harm CytomX’s business operations and financial condition.
The average CTMX stock price target is $4.69, implying 605.37% upside potential.
To learn more about CytomX Therapeutics Inc.’s risk factors, click here.